LabCorp ADAMTS13 Test
Laboratory Corporation of America began offering the ADAMTS13 test for a rare life-threatening blood-clotting disorder. The test distinguishes diseases characterized by acute thrombotic microangiopathy (TMA), a relatively rare syndrome in which small blood vessels develop blood clots. The test can provide faster and more accurate results, compared to other tests, to rule in or out the diagnosis of thrombotic thrombocytopenia purpura, a condition that can cuase TMA, and to support decisions whether to start patients on certain therapies, LabCorp said. The test is run on liquid chromatography-tandem mass spectrometry technology.